More "Competition" for TheraVitae

This is good news for all of you heart patients out there. There is yet another copycat of Theravitae--

CLEVELAND--(BUSINESS WIRE)--Arteriocyte, Inc., a clinical stage research and development company focused on creating stem cell therapies for the treatment of vascular diseases, announced today that it has reached the three month patient follow-up point for its SEACOAST Phase I clinical trial. The study is evaluating the safety of ACY001, Arteriocyte’s lead cellular therapy product. ACY001 is an adult stem cell therapy harvested from bone marrow to treat chronic ischemia, a serious form of heart disease.
The company also announced that an update on the clinical trial will be presented at the TCT2006 meeting in Washington, D.C. on October 27.


Just for the record, Theravitae presented an "update" on our clinical trial at the American Heart Association Scientific Sessions in November, 2005 -- almost one year ago.


Read the whole thing